念珠菌耐药机制的研究进展

摘要/Abstract

摘要： 近年来,真菌感染尤其是机会性真菌感染的发生率和病死率呈不断上升的趋势,这主要与真菌耐药和抗真菌药物品种有限有关.念珠菌是人体内的重要条件致病真菌,其常见的耐药机制包括靶酶的改变、靶位的缺乏、真菌细胞膜对药物的通透性下降、多药耐药蛋白表达增高、固醇合成旁路下游的改变、生物膜的形成等,最新文献报道分泌型天冬氨酸蛋白酶在念珠菌的耐药形成中存在一定作用.该文就念珠菌感染的流行病学和念珠菌的耐药机制两个方面进行综述.

关键词: 念珠菌, 真菌耐药, 耐药机制, 分泌型天冬氨酸蛋白酶

Abstract: In recent years,the incidence and mortality of fungal infection,especially the opportunistic fungal infection have been increasing.This is mainly associated with antifungal resistance and the restricted number of available antifungal drugs.Candida species are opportunistic fungi in human body.The common antifungal resistance mechanisms include the changes of the target enzyme,the lack of target site,the drug permeability decline of fungal cell membrane,the increased expression of multi-drug resistance protein,the change of cholesterol synthesis bypass,the biofilm formation and so on.The latest literature reports that secreted aspartic proteinases have a role in antifungal resistance of Candida spp..In this article,the epidemiology of Candida spp.infection and its possible antifungal resistance mechanisms are reviewed briefly.

Key words: Candida spp, antifungal resistance, resistance mechanisms, secreted aspartic proteinase

中图分类号:

R379.4

贺小圆, 赵明峰. 念珠菌耐药机制的研究进展[J]. 中国真菌学杂志, 2015, 10(1): 49-53.

HE Xiao-yuan, ZHAO Ming-feng. The research progress on antifungal resistance mechanisms of Candida spp.[J]. Chinese Journal of Mycology, 2015, 10(1): 49-53.

参考文献

[1] Sardi JC,Scorzoni L,Bernardi T,et al.Candida species:current epidemiology,pathogenicity,biofilm formation,natural antifungal products and new therapeutic options[J].J Med Microbiol,2013,62(Pt1):10-24.
[2] Silva NC,Nery JM,Dias AL.Aspartic proteinases of Candida spp.:role in patnogenicity and antifungal resistance[J].Mycoses,2014,57(1):1-11.
[3] Bondaryk M,Kurz tkowski W,Staniszewska M.Antifungal agents commonly used in the superficial and mucosal candidiasis treatment:mode of action andresistance development[J].Postepy Dermatol Alergol,2013,30(5):293-301.
[4] Pfaller MA,Diekema DJ,Procop GW,et al.Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B,flucytosine,and voriconazole against Candida spp[J].J Clin Microbiol,2007,45(11):3522-3528.
[5] Silva S,Negri M,Henriques M,et al.Candida glabrata,Candida parapsilosis and Candida tropicalis:biology,epidemiology,pathogenicity and antifungal resistance[J].FEMS Microbiol Rev,2012,36(2):288-305.
[6] Tortorano AM,Kibbler C,Peman J,et al.Candidaemia in Europe:epidemiology and resistance[J].Int J Antimicrob Agents,2006,27(5):359-366.
[7] Horn DL,Neofytos D,Anaissie EJ,et al.Epidemiology and outcomes of candidemia in 2019 patients:data from the prospective antifungal therapy alliance registry[J].Clin Infect Dis,2009,48(12):1695-1703.
[8] Cornistein W,Mora A,Orellana N,et al.Candida:epidemiology and risk factors for non-albicans species[J].Enferm Infecc Microbiol Clin,2013,31(6):380-384.
[9] Bal AM.The echinocandins:three useful choices or three too many?[J].Int J Antimicrob Agents,2010,35(1):13-18.
[10] Katiyar SK,Alastruey-Izquierdo A,Healey KR,et al.Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata:implications for echinocandin resistance[J].Antimicrob Agents Chemother,2012,56(12):6304-6309.
[11] Garcia-Effron G,Lee S,Park S,et al.Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase:implication for the existing susceptibility breakpoint[J].Antimicrob Agents Chemother,2009,53(9):3690-3699.
[12] Cannon RD,Lamping E,Holmes AR,et al.Efflux-mediated antifungal drug resistance[J],Clin Microbiol Rev,2009,22(2):291-321.
[13] Mansfield BE,Oltean HN,Oliver BG,et al.Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi[J].PLoS Pathog,2010,6(9):e1001126.
[14] Hameed S,Fatima Z.Novel Regulatory Mechanisms of Pathogenicity and Virulence to Combat MDR in Candida albicans[J].Int J Microbiol,2013,2013:240209.
[15] Manoharlal R,Gaur NA,Panwar SL,et al.Transcriptional activation and increased mRNA stability contribute to overexpression of CDR1 in azole-resistant Candida albicans[J].Antimicrob Agents Chemother,2008,52(4):1481-1492.
[16] Manoharlal R,Gorantala J,Sharma M,et al.PAP1[poly(A)polymerase 1]homozygosity and hyperadenylation are major determinants of increased mRNA stability of CDR1 in azole-resistant clinical isolates of Candida albicans[J].Microbiology,2010,156(Pt2):313-326.
[17] Coste A,Turner V,Ischer F,et al.A mutation in Tac1p,a transcription factor regulating CDR1 and CDR2,is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans[J].Genetics,2006,172(4):2139-2156.
[18] Lo HJ,Wang JS,Lin CY,et al.Efg1 involved in drug resistance by regulating the expression of ERG3 in Candida albicans[J].Antimicrob Agents Chemother,2005,49(3):1213-1215.
[19] Ramage G,Rajendran R,Sherry L,et al.Fungal biofilm resistance[J].Int J Microbiol,2012,2012:528521.
[20] Wu T,Wright K,Hurst S,et al.Enhanced extracellular production of aspartyl proteinase,a virulence factor,by Candida albicans isolates following growth in subinhibitory concentrations of fluconazole[J].Antimicrob Agents Chemother,2000,44(5):1200-1208.
[21] Costa CR,Jesuíno RSA,Lemos J,et al.Effects of antifungal agents in Sap activity of Candida albicans isolates[J].Mycopathologia,2010,169(2):91-98.
[22] Kumar R,Shukla PK.Amphotericin B resistance leads to enhanced proteinase and phospholipase activity and reduced germ tube formation in Candida albicans[J].Fungal Biol,2010,114(2-3):189-197.
[23] Becker JM,Henry LK,Jiang W,et al.Reduced virulence of Candida albicans mutants affected in multidrug resistance[J].Infect Immun,1995,63(11):4515-4518.
[24] Puri S,Kumar R,Chadha S,et al.Secreted aspartic protease cleavage of Candiada albiicans Msb2 activates Cek1 MAPK signaling affecting biofilm formation and oropharyngeal candidasis[J].PLoS One,2012,7(11):e46020.